Abstract Number: 893 • 2016 ACR/ARHP Annual Meeting
Preliminary Results of a Multi Modal Imaging Study Suggests a Better Accuracy for the Diagnosis of Giant Cell Arteritis
Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in patient over 50 years of age. It is a medical emergency as it…Abstract Number: 894 • 2016 ACR/ARHP Annual Meeting
Laboratory Tests in Giant Cell Arteritis – Do They Make the Cut?
Background/Purpose: The initial suspicion of Giant cell arteritis (GCA) is often made in the setting of primary care or casualty by a non-rheumatologist. Whilst temporal…Abstract Number: 895 • 2016 ACR/ARHP Annual Meeting
Incidence of Osteoporotic Mayor Fractures in a Cohort of Patients with Polymyalgia Rheumatica
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease associated with older age and long term use of glucocorticoids. As such a high incidence of osteoporosis…Abstract Number: 896 • 2016 ACR/ARHP Annual Meeting
Risk for Cardiovascular Disease in Giant Cell Arteritis and Polymyalgia Rheumatica
Background/Purpose: chronic inflammatory diseases are at a substantially increased risk of cardiovascular events (CVE). Scarce data is available in patients with Giant cell arteritis (GCA)…Abstract Number: 897 • 2016 ACR/ARHP Annual Meeting
Discordance Rates of Bilateral Temporal Artery Biopsies: A Retrospective Analysis
Background/Purpose: Previous retrospective studies have suggested that simultaneous bilateral temporal artery biopsy (TAB) may lead to increased detection rates of giant cell arteritis (GCA). The term…Abstract Number: 898 • 2016 ACR/ARHP Annual Meeting
Treatment and Outcome of Patients with a Diagnosis of Healed Arteritis on Temporal Artery Biopsy
Background/Purpose: Temporal artery biopsy (TAB) is the gold standard for the diagnosis of Giant Cell Arteritis (GCA), yet is limited by the presence of skip…Abstract Number: 899 • 2016 ACR/ARHP Annual Meeting
Disparities in Disease Characteristics, Treatment Pattern and Comorbidities in 1,858 Patients with Polymyalgia Rheumatica, Giant Cell Arteritis or Both Diseases
Background/Purpose: Methods: Conclusion:Abstract Number: 900 • 2016 ACR/ARHP Annual Meeting
The Phenotype of Macrophages in the Inflamed Vascular Wall of Giant Cell Arteritis Resembles the Phenotype of Non-Classical Monocytes
Background/Purpose: Macrophages are critical tissue destructive cells in the immunopathology of patients with giant cell arteritis (GCA). Macrophage precursors, monocytes, can be subclassified in three…Abstract Number: 901 • 2016 ACR/ARHP Annual Meeting
Clinical Features of Takayasu’s Arteritis from an Inception Cohort: Early Disease Is Characterized By ‘systemic Inflammation’
Background/Purpose: There is only retrospective and very limited data for the long term prognosis of Takayasu's Arteritis (TAK), a rare large-vessel vasculitis. In this study,…Abstract Number: 902 • 2016 ACR/ARHP Annual Meeting
High Disease Activity Scores and Leptin Levels in Takayasu Patients with Overweight and Obesity
Background/Purpose: We aimed to determine the prevalence of overweight, obesity and metabolic syndrome (MetS) and leptin levels in patients with Takayasu arteritis (TA) and their…Abstract Number: 903 • 2016 ACR/ARHP Annual Meeting
Temporal Arteritis: Is There Any Correlation Between Ultrasonographic Arterial Wall Involvement and the Inflammatory Cellular Infiltrate at Histological Examination?
Background/Purpose: Ultrasonographic alterations such as the halo sign and the compression test are now accepted as surrogate markers of artery inflammation. No data have yet…Abstract Number: 904 • 2016 ACR/ARHP Annual Meeting
Clinical Features and Mortality of 411 Chinese Takayasu’s Arteritis Patients
Background/Purpose: To investigate the clinical features and long-term outcome of Chinese Takayasu arteritis (TAK) patients. Methods: Medical records of 411 Chinese TAK in-patients (325 female,…Abstract Number: 905 • 2016 ACR/ARHP Annual Meeting
Platelet Activation, As Measured By Plasma Soluble Glycoprotein VI, Is Not Associated with Disease Activity or Ischaemic Events in Giant Cell Arteritis
Background/Purpose: Patients with Giant Cell Arteritis (GCA) have an increased risk of devastating cranial ischaemic complications including vision loss and stroke. The BSR guidelines recommend…Abstract Number: 906 • 2016 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Background/Purpose: Several Clinical trials indicate that Methotrexate (MTX) could be considered as a feasible option in addition to corticosteroids for patients with GCA, but there…Abstract Number: 907 • 2016 ACR/ARHP Annual Meeting
Rituximab in Patients with Takayasu Arteritis: A Single Center Experience on Five Patients
Background/Purpose: Takayasu arteritis (TAK) is a large vessel vasculitis involving the aorta and its major branches in patients younger than 40 years. Glucocorticoids (GCs) are…
ACR Meeting Abstracts